Hyperbaric Bupivicaine

ApprovedSmall molecule

UUniversity of Witwatersrand, South Africa

Hyperbaric Bupivicaine is one of 45 small molecule programs targeting Cesarean Section. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cesarean SectionActive, not recruiting

Cesarean SectionApproved

Active, not recruiting

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Hyperbaric Bupivicaine

UUniversity of Witwatersrand, South Africa

Approved

1 2

Marcaine

IInnocoll

Preclinical

21 3

Pitocin

RRetrophin

Preclinical

16 4

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

12 5

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

11 6

Dynastat

Pfizer

Preclinical

1 7

Duragesic

CCephalon

Preclinical

6 8

Catapres

Boehringer Ingelheim

Preclinical

4 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalNot yet recruiting

Cesarean Section

NCT07094802

Clinical

Trials by Indication[1]

Cesarean Section1 trial

Comparison of Intrathecal Bupivacaine With and Without Morphine for Post-operative Analgesia in Parturients Undergoing Elective Cesarean Section: A Randomized Controlled Trial

Not yet recruiting·TTribhuvan University Teaching Hospital, Institute Of Medicine.·Phase 4·NCT07094802·92 enrolled

Opioid1 trial

Intrathecal Opioid Study

Completed·UUniversity of Witwatersrand, South Africa·Phase 4·NCT02577809·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hyperbaric Bupivicaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperbaric Bupivicaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperbaric Bupivicaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Witwatersrand, South Africa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Witwatersrand, South Africa

Hyperbaric Bupivicaine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Cesarean Section1 trial

Opioid1 trial

References

Drug Info

Quick Facts

Related News